GS2-05: "Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian..."

GS2-05: "Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian..."Подробнее

GS2-04: "Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor..."Подробнее

Breast cancer: Adjuvant exemestane combined with ovarian function suppression better than tamoxifenПодробнее

NEJM Trial Summary: Duration of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast CancerПодробнее

What is Exemestane? 💊 #breastcancerПодробнее

Switching to a Different Aromatase Inhibitor: Oncologist ExplainsПодробнее

How to advance adjuvant hormonal therapy for BREAST CANCER? Improvement over TamoxifenПодробнее

Breast Cancer Treatment updates from ASCO 2014Подробнее

Adjuvant exemestane more effective than tamoxifen (combined with ofs) in women with breast cancerПодробнее

Olivia Pagani, et al.Подробнее

My Biggest Cancer MistakeПодробнее

Are Aromatizer Inhibitors Even Worth It?? 🤔 #ShortsПодробнее

GS3 -05: "Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection..."Подробнее

Dr. Harvey on Aromatase Inhibitor Treatment DurationПодробнее

Entinostat addition fails to improve AI-resistant breast cancer outcomes | Roisin ConnollyПодробнее

Adjuvant Endocrine Therapy and Risk of Contralateral Breast CancerПодробнее

What is Exemestane?Подробнее

Adjuvant Aromatase InhibitorsПодробнее

What to do in a high risk early BC patient who has poor tolerance to ovarian function suppression ?Подробнее

Which strategy do you use to include Aromatase inhibitor in the adjuvant treatment of early BC ?Подробнее